CD8+ Serum as a predictor of Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer

Abstract

Abstract CD8+ Cytotoxic T-cell Lymphocytes (CTLs) had a major role in tumour apoptosis. Meanwhile, chemotherapy could induce tumour cell apoptosis and enhance CTL response. Therefore, pre-treatment immune status might predict the ability of chemotherapy to eliminate cancer cells. The aim of this study was to evaluate the efficacy of neoadjuvant chemotherapy to CD8+ serum in locally advanced breast cancer patient. A randomized clinical trial has been conducted in Dr Mohammad Hoesin Palembang from October 2017 until January 2018. There were 30 samples who fulfil the inclusion criteria. All samples were taken neoadjuvant chemotherapy and analysis data was using SPSS ver.21. The range of age patient with locally advanced breast cancer in this study 30-66 y.o with mean 45±10.526 y.o. After neoadjuvant chemotherapy, the CD8+ serum was significantly decreased (p=0.000). CD8+ serum before chemotherapy has sensitivity 42.86% and specificity 43.48% to predict neoadjuvant chemotherapy response with cut off point 660.7 cell/mm3. Neoadjuvant chemotherapy decreases CD8+ significantly in locally advanced breast cancer patient.